RJFSA
KLRS

Raymond James Financial Services Advisors’s Kalaris Therapeutics KLRS Stock Holding History

Raymond James Financial Services Advisors’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$48.9K Hold
2,630
– – ﹤0.01% 3361
2024
Q2 		$43.8K Hold
2,630
– – ﹤0.01% 3308
2024
Q1 		$45.7K Buy
2,630
+1,176
+81% +$19.2K ﹤0.01% 3303
2023
Q4 		$22.7K Buy
+1,454
New +$57.3K ﹤0.01% 3230

Other funds holding KLRS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AI
Acuitas Investments Seattle, Washington $1.43M AUM 17.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Raymond James Financial Services Advisors's KLRS Position: Q3 2024 in Review

Raymond James Financial Services Advisors held its Kalaris Therapeutics (KLRS) position steady in Q3 2024 at 2,630 shares worth $48.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3361.

Raymond James Financial Services Advisors first reported a position in KLRS in Q4 2023 and has held it in 4 quarters since. 59 funds tracked by Wall St. Rank hold KLRS as of Q3 2024.

  • Raymond James Financial Services Advisors held 2,630 shares of Kalaris Therapeutics worth $48.9K as of Q3 2024.
  • Raymond James Financial Services Advisors left its Kalaris Therapeutics share count unchanged in Q3 2024.
  • Kalaris Therapeutics made up ﹤0.01% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #3361 holding.
  • Raymond James Financial Services Advisors first reported a position in Kalaris Therapeutics in Q4 2023 and has held it in 4 quarters since.
  • 59 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q3 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.